IL-18 gene polymorphism, cardiovascular mortality and coronary artery disease

European Journal of Clinical Investigation

Volumn 40, Issue 11, 2010, Pages 994-1001

  Hernesniemi, Jussi A ^a,b   Anttila, Kaisa ^a,b   Nieminen, Tuomo ^b   Kähönen, Mika ^a,b   Mononen, Nina ^a,b   Nikus, Kjell ^a   Turjanmaa, Väinö ^a,b   Viik, Jari ^b   Lehtinen, Rami ^a,b,c   Lehtimäki, Terho ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY OF APPLIED SCIENCES   (Finland)

Author keywords

Atherosclerosis; Coronary artery disease; Interleukin 18; Mortality; Polymorphism

Indexed keywords

INTERLEUKIN 18;

ADULT; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ATHEROSCLEROSIS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS;

EID: 78649432344     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02356.x     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep 2002;51:123-6.
2. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest 2005;115:2305-15.
3. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
4. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002;90:1039-40.
5. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19.
6. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-20.
7. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Schnabel R, Munzel T et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007;195:e126-34.
8. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281-312.
9. McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today 2000;21:312-5.
10. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-50.
11. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57.
12. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-603.
13. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711-21.
14. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007;27:2043-9.
15. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006;188:450-4.
16. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006;83:447S-55S.
17. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989;57:590-5.
18. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
19. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol 2005;98:45-8.
20. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002;88:467-9.
21. Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T et al. Interleukin 18 in acute myocardial infarction. Heart 2000;84:668.
22. Chen MC, Chen CJ, Yang CH, Wu CJ, Fang CY, Hsieh YK et al. Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels 2007;22:371-5.
23. Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R et al. Promoter Polymorphism of Interleukin-18 in Angiographically Proven Coronary Artery Disease. Angiology 2009;60:180-5.
24. Nieminen T, Lehtinen R, Viik J, Lehtimaki T, Niemela K, Nikus K et al. The Finnish Cardiovascular Study (FINCAVAS): characterising patients with high risk of cardiovascular morbidity and mortality. BMC Cardiovasc Disord 2006;6:9.
25. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
26. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, Von Elm E et al. STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest 2009;39:247-66.
27. Fan M, Kahonen M, Rontu R, Lehtinen R, Viik J, Niemi M et al. The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. Am Heart J 2006;152:538-42.
28. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999;14:143-9.
29. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12:132-7.
30. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
31. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
32. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007;23:1038-9.
33. Foley TE, Greenwood BN, Day HE, Koch LG, Britton SL, Fleshner M. Elevated central monoamine receptor mRNA in rats bred for high endurance capacity: implications for central fatigue. Behav Brain Res 2006;174:132-42.
34. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003;59:234-40.
35. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89:E41-5.
36. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002;90:E34-8.
37. De Nooijer R, Von Der Thusen JH, Verkleij CJ, Kuiper J, Jukema JW, Van Der Wall EE et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:2313-9.
38. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 2005;25:791-6.
39. Hernesniemi JA, Karhunen PJ, Oksala N, Kahonen M, Levula M, Rontu R et al. Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. Eur Heart J 2009;30:2939-46.
40. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S et al. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study. Atherosclerosis 2008;196:643-9.
41. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A et al. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun 2006;342:1413-6.
42. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146-52.
43. Thompson SR, McCaskie PA, Beilby JP, Hung J, Jennens M, Chapman C et al. IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease. Clin Chem 2007;53:2078-85.
44. Thompson SR, Novick D, Stock CJ, Sanders J, Brull D, Cooper J et al. Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol 2007;27:2743-9.